BioArctic ABBRCTF 84 FCF Margin % is -37.94% as of Mar. 2026. GuruFocus rates BRCTF with a GF Score™ of 84/100 and a GF Value™ of $49.30 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 959 Biotechnology companies, BioArctic AB ranks better than 98.75% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. BioArctic AB's Free Cash Flow for the
three
months ended in Mar. 2026 was $-17.8 Mil. BioArctic AB's Revenue for the
three
months ended in Mar. 2026 was $47.0 Mil. Therefore, BioArctic AB's FCF Margin % for the quarter that ended in Mar. 2026 was -37.94%.
The historical rank and industry rank for BioArctic AB's FCF Margin % or its related term are showing as below:
BRCTF'
s FCF Margin % Range Over the Past 10 Years
Min: -625.78 Med: -24.03 Max: 636.44
Current: 107.85
During the past 11 years, the highest FCF Margin % of BioArctic AB was 636.44%. The lowest was -625.78%. And the median was -24.03%.
BRCTF's FCF Margin % is ranked better than 98.75% of 959
companies
in the Biotechnology industry
Industry Median: -84.65
vs BRCTF: 107.85
BioArctic AB FCF Margin % Related Terms
BioArctic AB FCF Margin % Historical Data
* Premium members only.
The historical data trend for BioArctic AB's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BRCTF vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, BioArctic AB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioArctic AB FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioArctic AB's FCF Margin % distribution charts can be found below:
* The bar in red indicates where BioArctic AB's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioArctic AB (BRCTF) has a FCF Margin % of -37.94% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on BioArctic AB and its competitors. According to the industry distribution chart, BioArctic AB ranks #12 out of 959 companies in the Biotechnology industry, placing it in the top 1.3%.
Is BioArctic AB's FCF Margin % too high?
BioArctic AB's current FCF Margin % is -37.94%. Based on the distribution chart, BioArctic AB ranks #12 out of 959 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioArctic AB has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioArctic AB's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioArctic AB ranks #12 out of 959 companies for FCF Margin %. This places BioArctic AB in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on BioArctic AB and its competitors. BioArctic AB's current FCF Margin % is -37.94%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioArctic AB stock overvalued right now?
Based on GuruFocus' analysis, BioArctic AB (BRCTF) is currently considered Modestly Undervalued. The stock's GF Value™ is $49.30, compared to a current price of $35.00 — trading 29% below its estimated fair value. The current FCF Margin % is -37.94%. BioArctic AB's overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For BioArctic AB (BRCTF), the current FCF Margin % is -37.94% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioArctic AB (BRCTF) Overvalued in 2026?
Based on GuruFocus' analysis, BioArctic AB stock appears to be undervalued.
The current stock price of $35.00 is trading 29% below its estimated GF Value™ of $49.30.
GuruFocus considers BioArctic AB to be Modestly Undervalued.
Key valuation signals for BRCTF:
FCF Margin %: -37.94%
GF Value™: $49.30 vs. price of $35.00 (29% below fair value)
No single metric tells the full story. See the BRCTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS. Geographically, it derives a majority of its revenue from North America.
84GF Score
Get the complete analysis for BRCTF
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BRCTF has been successfully added to your 
